share_log

榮昌生物：(經修訂) 截至二零二三年十二月三十一日止月份之股份發行人的證券變動月報表

REMEGEN: (Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2023

香港交易所 ·  Apr 8 04:40
Summary by Moomoo AI
榮昌生物製藥（煙台）股份有限公司於2024年4月8日重新提交了截至2023年12月31日的股份變動月報表。報告顯示，公司的H類普通股股份數目在香港聯交所上市的狀態保持不變，結存為189,581,239股，面值為1人民幣。A類普通股在上海證券交易所上市，同樣未見增減，結存為354,681,764股。此外，報告提及了2022年及2023年的A股股票激勵計劃，包括首次授予及預留授予的限制性股票數目，但本月內並無新股份發行。報告確認，所有證券發行均獲得董事會授權，並符合相關法律規定。
榮昌生物製藥（煙台）股份有限公司於2024年4月8日重新提交了截至2023年12月31日的股份變動月報表。報告顯示，公司的H類普通股股份數目在香港聯交所上市的狀態保持不變，結存為189,581,239股，面值為1人民幣。A類普通股在上海證券交易所上市，同樣未見增減，結存為354,681,764股。此外，報告提及了2022年及2023年的A股股票激勵計劃，包括首次授予及預留授予的限制性股票數目，但本月內並無新股份發行。報告確認，所有證券發行均獲得董事會授權，並符合相關法律規定。
WING CHEONG BIOPHARMACEUTICAL (YANTAI) CO., LTD. REFILED ON APRIL 8, 2024 THE REPORT OF CHANGES IN SHARES FOR THE MONTH ENDED DECEMBER 31, 2023. The report showed that the company's number of Class H ordinary shares listed on the Hong Kong Stock Exchange remained unchanged, with 189,581,239 shares deposited with an equivalent value of RMB 1. Class A ordinary shares were listed on the Shanghai Stock Exchange with an unprecedented increase of 354,681,764 shares. In addition, the report mentions the A-share incentive plan for 2022 and 2023, including a limited number of initial and reserved shares granted, but no new shares were issued this month. The report confirms that all securities issuances are authorized by the Board of Directors and comply with relevant legal requirements.
WING CHEONG BIOPHARMACEUTICAL (YANTAI) CO., LTD. REFILED ON APRIL 8, 2024 THE REPORT OF CHANGES IN SHARES FOR THE MONTH ENDED DECEMBER 31, 2023. The report showed that the company's number of Class H ordinary shares listed on the Hong Kong Stock Exchange remained unchanged, with 189,581,239 shares deposited with an equivalent value of RMB 1. Class A ordinary shares were listed on the Shanghai Stock Exchange with an unprecedented increase of 354,681,764 shares. In addition, the report mentions the A-share incentive plan for 2022 and 2023, including a limited number of initial and reserved shares granted, but no new shares were issued this month. The report confirms that all securities issuances are authorized by the Board of Directors and comply with relevant legal requirements.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more